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In phase II cancer trials, tumour response is either the
primary or an important secondary endpoint. Tumour
response is a binary composite endpoint determined,
according to the RECIST criteria, by 1) whether the per-
centage change in tumour size is greater than a prescribed
threshold and 2) (binary) criteria such as whether a patient
develops new lesions.
Further binary criteria, such as death or serious toxi-
city, may be added to these criteria. The probability of
tumour response (i.e. `success’ on the composite end-
point) would usually be estimated simply as the propor-
tion of successes among patients. This approach uses
the tumour size variable only through a discretised
form, viz. whether or not it is above the threshold. In
this presentation, we discuss a method which also esti-
mates the probability of success but which gains preci-
sion by using the information on the undiscretised (i.e.
continuous) tumour size variable. This approach can
also be used to increase the power to detect a difference
between the probabilities of success under two different
treatments in a comparative trial. We demonstrate these
increases in precision and power using simulated data.
We also apply the method to real data from a phase II
cancer trial, and show that it results in a considerably
narrower confidence interval for the probability of
tumour response. Extending the work to other endpoints
used in phase II trials, such as progression-free survival
will be discussed.
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